These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24671900)

  • 21. Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention: The ExcelsiorLOAD Trial.
    Hochholzer W; Amann M; Titov A; Younas I; Löffelhardt N; Riede F; Potocnik C; Stratz C; Hauschke D; Trenk D; Neumann FJ; Valina CM
    JACC Cardiovasc Interv; 2016 Feb; 9(3):219-227. PubMed ID: 26777322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
    Bonello L; Laine M; Baumstarck K; Fernandez J; Maillard L; Peyrol M; Bessereau J; Aradi D; Camilleri E; Roubille F; Piot C; Paganelli F; Camoin-Jau L; Dignat-George F
    Int J Cardiol; 2013 Oct; 168(4):4244-8. PubMed ID: 23911273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
    Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
    Danese E; Fava C; Beltrame F; Tavella D; Calabria S; Benati M; Gelati M; Gottardo R; Tagliaro F; Guidi GC; Cattaneo M; Minuz P
    J Thromb Haemost; 2016 Feb; 14(2):282-93. PubMed ID: 26576037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
    Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
    Nakamura M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Ikeda Y; Saito S
    Int J Cardiol; 2015 Mar; 182():541-8. PubMed ID: 25679803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of platelet aggregation response in switching regimen from prasugrel to clopidogrel between CYP2C19 extensive versus non-extensive metabolizers.
    Ebisawa S; Ueki Y; Mochidome T; Senda K; Nishimura H; Saigusa T; Miura T; Motoki H; Koyama J; Ikeda U
    Cardiovasc Interv Ther; 2018 Jul; 33(3):277-284. PubMed ID: 28681220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
    Paarup Dridi N; Johansson PI; Lønborg JT; Clemmensen P; Radu MD; Qayyum A; Pedersen F; Kollslid R; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2015; 26(6):521-9. PubMed ID: 25166751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
    Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
    Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry.
    Motovska Z; Ondrakova M; Bednar F; Knot J; Ulman J; Maly M
    Thromb Res; 2015 Jun; 135(6):1093-9. PubMed ID: 25917561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
    Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y
    Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.